Biotech Values

[jq1234]

Obviously many issues are touched by inversion, I only focus on drug companies in my post because pricing model is different from other industries - US consumers pay competitive if not lower price in most industries except drugs vs other developed countries.

The other issues that really gets to me is corporate governance issues. IMO paying executives' tax liabilities is much worse than inversion itself - I don't have problem with inversion in general term because at least you can argue inversion is for ALL shareholders. Among things I want change the most in US is corporate governance!